Results 51 to 60 of about 21,298 (206)
Frontiers in Oncology, 2022 The prognosis for female patients with locoregionally recurrent breast cancer has improved with the concurrent local and systemic treatment under multiple disciplinary teams.
Jingxian Ding, Yali Cao, Yonghong Guo
doaj +1 more source
Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer [PDF]
, 2017 Hormone therapy targeting estrogen receptor (ER) is the principal treatment for ER-positive breast cancers. However, many cancers develop resistance to hormone therapy while retaining ER expression. Identifying new druggable mediators of ER function can
Arteaga +37 more
core +2 more sources
iMetaMed, EarlyView.Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen +4 more
wiley +1 more source
Frontiers in Oncology, 2023 AimTo evaluate the cost-effectiveness of palbociclib plus fulvestrant in the second-line treatment of women with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer based on the latest published follow ...
Wentao Zhu +6 more
doaj +1 more source
Asia-Pacific Journal of Clinical Oncology, EarlyView.This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott +8 more
wiley +1 more source
Therapeutic Advances in Medical Oncology, 2017 We reviewed randomized phase II/III trials comparing first- or second-line endocrine therapy as monotherapy or in combination with targeted therapies for treatment of postmenopausal patients with hormone receptor-positive advanced breast cancer.
Tomás Reinert, Carlos H. Barrios
doaj +1 more source
Current Oncology, 2022 Background: Palbociclib, a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor, in combination with letrozole or fulvestrant has been demonstrated to prolong the progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human ...
Fulbert Fu +3 more
doaj +1 more source
Estrogen plus estrogen receptor antagonists alter mineral production by osteoblasts in vitro. [PDF]
, 2011 In early postmenopausal women, estrogen withdrawal is associated with increased bone turnover leading to bone loss and increased risk of fracture. Recent studies have suggested that the remaining bone tissue is significantly stronger, stiffer and has an ...
Brennan, Orlaith +2 more
core +2 more sources
International Journal of Cancer, Volume 159, Issue 1, Page 210-223, 1 July 2026.What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching +20 more
wiley +1 more source
Pharmacophore modeling for identification of anti-IGF-1R drugs and in-vitro validation of fulvestrant as a potential inhibitor. [PDF]
PLoS ONE, 2018 Insulin-like growth factor 1 receptor (IGF-1R) is an important therapeutic target for breast cancer treatment. The alteration in the IGF-1R associated signaling network due to various genetic and environmental factors leads the system towards metastasis.
Samra Khalid +4 more
doaj +1 more source